Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL29446115 | 0.98 | S1PR1 (0.76) | S1PR1S1PR3 | |
| Hydrochloric Acid SCHEMBL947478 | 0.98 | S1PR1 (0.76) | S1PR1S1PR3 | |
| SCHEMBL22829433 | 0.98 | S1PR1 (0.80) | S1PR1S1PR3 | |
| Ammonia Solution, Strong SCHEMBL30815905 | 0.97 | S1PR1 (0.79) | S1PR1S1PR3 | |
| SCHEMBL21296069 | 0.91 | S1PR1 (0.67) | S1PR1S1PR3 | |
| SCHEMBL949508 | 0.88 | S1PR1 (1.00) | S1PR1S1PR3 | |
| Biphenyl SCHEMBL27642578 | 0.88 | S1PR1 (0.77) | S1PR1S1PR3 | |
| SCHEMBL1871664 | 0.88 | S1PR1 (0.86) | S1PR1S1PR3 | |
| SCHEMBL21300600 | 0.88 | S1PR1 (0.65) | S1PR1S1PR3 | |
| SCHEMBL30816058 | 0.88 | S1PR1 (0.65) | S1PR1S1PR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240327342-A1 | COMPOUNDS HAVING S1P5 RECEPTOR AGONISTIC ACTIVITY | ONO PHARMACEUTICAL CO., LTD. (JP) | 2024-10-03 | — | — | US | disclosed |
| EP-4431157-A2 | 1-[[(3S)-3-METHYL-6-(4(4,4-TRIFLUOROBUTOXY)-3,4-DIHYDRONAPHTHALEN-2YL]METHYL]AZETIDINE-3-CARBOXYLIC ACID HAVING S1P5 RECEPTOR AGONIST ACTIVITY FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS AND CANCER | ONO Pharmaceutical Co., Ltd. (JP) | 2024-09-18 | — | — | EP | disclosed |
| US-12049445-B2 | Compounds having S1P5 receptor agonistic activity | ONO PHARMACEUTICAL CO., LTD. (JP) | 2024-07-30 | — | — | US | disclosed |
| CN-111757869-B | Compounds having S1P5 receptor agonistic activity | 小野药品工业株式会社 | 2024-03-08 | — | — | CN | disclosed |
| US-20220055986-A1 | COMPOUNDS HAVING S1P5 RECEPTOR AGONISTIC ACTIVITY | ONO PHARMACEUTICAL CO., LTD. (JP) | 2022-02-24 | — | — | US | disclosed |
| US-11198672-B2 | Compounds having S1P5 receptor agonistic activity | ONO PHARMACEUTICAL CO., LTD. (JP) | 2021-12-14 | — | — | US | disclosed |
| US-11198672-B2 | Compounds having S1P5 receptor agonistic activity | ONO PHARMACEUTICAL CO., LTD. (JP) | 2021-12-14 | — | — | US | disclosed |
| US-20210087141-A1 | COMPOUNDS HAVING S1P5 RECEPTOR AGONISTIC ACTIVITY | ONO PHARMACEUTICAL CO., LTD. (JP) | 2021-03-25 | — | — | US | disclosed |
| US-20210087141-A1 | COMPOUNDS HAVING S1P5 RECEPTOR AGONISTIC ACTIVITY | ONO PHARMACEUTICAL CO., LTD. (JP) | 2021-03-25 | — | — | US | disclosed |
| EP-3757091-A1 | COMPOUND HAVING S1P5 RECEPTOR AGONIST ACTIVITY | ONO Pharmaceutical Co., Ltd. (JP) | 2020-12-30 | — | — | EP | disclosed |
| EP-3757091-A1 | COMPOUND HAVING S1P5 RECEPTOR AGONIST ACTIVITY | ONO Pharmaceutical Co., Ltd. (JP) | 2020-12-30 | — | — | EP | disclosed |
| WO-2019163917-A1 | COMPOUND HAVING S1P5 RECEPTOR AGONIST ACTIVITY | 小野薬品工業株式会社 | 2019-08-29 | — | — | WO | disclosed |
| WO-2019163917-A1 | COMPOUND HAVING S1P5 RECEPTOR AGONIST ACTIVITY | 小野薬品工業株式会社 | 2019-08-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12049445-B2 | Compounds having S1P5 receptor agonistic activity | S1PR5, S1PR1, S1PR4 | S1PR1 2/4885S1PR3 6/4885 |
| US-20240327342-A1 | COMPOUNDS HAVING S1P5 RECEPTOR AGONISTIC ACTIVITY | S1PR5, S1PR1, S1PR4 | S1PR1 2/4885S1PR3 6/4885 |
| US-11198672-B2 | Compounds having S1P5 receptor agonistic activity | S1PR5, S1PR1, S1PR4 | S1PR1 2/4885S1PR3 6/4885 |
| US-20210087141-A1 | COMPOUNDS HAVING S1P5 RECEPTOR AGONISTIC ACTIVITY | S1PR5, S1PR1, S1PR4 | S1PR1 2/4885S1PR3 6/4885 |
| US-20220055986-A1 | COMPOUNDS HAVING S1P5 RECEPTOR AGONISTIC ACTIVITY | S1PR5, S1PR1, S1PR4 | S1PR1 2/4885S1PR3 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.